论文部分内容阅读
膀胱癌是泌尿系统最常见的肿瘤,术后易复发是其一重要特点,多重抗药性(MDR)使得化疗药物如丝裂霉素、噻替哌等预防复发的疗效不十分乐观,近年来,人们使用卡介苗等生物制剂取得了较好的疗效,其机理是通过调节膀胱癌患者的免疫功能而起作用。乌体林斯是一种多能性免疫刺激剂,我们自2000年4月至2001年6月,膀胱癌术后使用乌体林斯治疗,取得了一定的疗效,现总结报告如下:
Bladder cancer is the most common type of cancer in the urinary system. Postoperative recurrence is an important feature. Multidrug resistance (MDR) makes the efficacy of chemotherapeutic drugs such as mitomycin and thiotepa not very optimistic. In recent years, People using BCG and other biological agents have achieved good results, the mechanism is through the regulation of immune function in patients with bladder cancer and play a role. Wu Lin Linsi is a pluripotent immunostimulant, we from April 2000 to June 2001, after the use of Wu Taili Si bladder cancer treatment, and achieved some results, are summarized as follows: